Autologous stem cell transplantation in acute myocardial infarction: The ASTAMI randomized controlled trial. Intracoronary transplantation of autologous mononuclear bone marrow cells, study design and safety aspects

Figures & data

Figure 1. Study design. mBMC = mononuclear bone marrow cells.

Figure 2. Screening and inclusion flow chart. STEMI = ST-elevation myocardial infarction.

Table I.  Baseline characteristics of the study population.

	mBMC transplantation (n = 24)	Control group (n = 25)	p-value
Age, years	57±8	55±9	ns
Male sex, n (%)	21 (88)	21 (84)	ns
Previous CHD, n (%)	0	0	ns
Hypertension, n (%)	10 (42)	10 (40)	ns
Hyperlipidemia, n (%)	14 (58)	9 (36)	ns
Diabetes, n (%)	0 (0)	2 (8)	ns
Smokers, n (%)	10 (42)	13 (52)	ns
Time to revascularization, min	265±145	304±153	ns

mBMC = mononuclear bone marrow cells, CHD = coronary heart disease.

Continous variables are presented as mean±SD.

Table II.  Biochemical and clinical parameters related to the mBMC transplantation.

	mBMC transplantation (n = 24)
CK pre (U/l)	166 (121, 217)
CK post (U/l)	123 (103, 203)
CKMB pre (µg/l)	4,1 (3,7 , 5,2)
CKMB post (µg/l)	3,2 (2,5 , 4,0)
Chest pain during balloon inflation	n = 20 (87%)
Ischemic ECG changes* during balloon inflation	n = 16 (70%)

CK = creatine kinase, CKMB = creatine kinase MB mass isoenzyme, mBMC = mononuclear bone marrow cells, pre = morning before mBMC transplantation,

post = morning after mBMC transplantation.

CK and CKMB values are median (25, 75 percentile).

* ≥ 1 mm ST-segment elevation or depression at the J point + 60 ms in one or more standard leads.